Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment ...

In addition, Anteris today announced the closing of its previously announced sale, in a private placement (the “Private Placement”), of 15,652,173 shares of common stock to Medtronic plc (through a ...

Fourth quarter and full year 2025 investor conference call scheduled for February 25, 2026 at 4:30 p.m. ET Arcutis management to present at the Guggenheim Emerging Outlook: Biotech Summit on February ...

Importantly, the Centers for Medicare & Medicaid Services (CMS) has approved Category B IDE coverage for the BENEFIT-HF clinical trial under IDE regulations (42 CFR § 405 Subpart B), effective January ...

Fourth quarter 2025 GAAP net income attributable to Intuitive was $795 million, or $2.21 per diluted share, compared with $686 million, or $1.88 per diluted share, in the fourth quarter of 2024.

The Medtronic investment and the underwritten public offering of common stock position Anteris to continue to execute the global PARADIGM Trial and to continue investing in research that can transform ...

The study will be conducted in three phases. Part A is a Phase 2, open-label, semi-sequential dose-ranging portion of the study. Part B is the Phase 3, double-blind, randomized, placebo controlled ...

River Oaks Treatment Center, traditionally recognized for its expertise in treating substance use and co-occurring disorders, has recently broadened its mission to include specialized mental health ...

NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“ Psyence BioMed ” or the “ Company ”) today announced that it adjourned its annual and special meeting of ...

D Path, a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced its participation as an exploratory ...

Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced the initiation of a key usability ...

Roji Health Intelligence, a healthcare technology firm focused on value-based care and quality performance, today announced that it has been re-certified as a Centers for Medicare & Medicaid Services ...